Skip to main content
SpringerLink
Log in

Suppression by the spironolactone metabolite canrenone of plasma testosterone in man

  • Short Communication
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Summary

Healthy male subjects were given orally a single dose of 5 mg canrenone per kg body weight. Canrenone caused a significant decrease in plasma testosterone concentration already 3 hrs after administration of the drug. Suppression of plasma testosterone concentration by 50 to 60 per cent persisted over 9 hrs.

It is concluded that suppression of testosterone production is an important factor in the antiandrogenic activity of spirolactones in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Basinger, G. T., Gittes, R. F.: Antiandrogenic effect of spironolactone in rats. J. Urol. (Baltimore) 111, 77–80 (1974)

    Google Scholar 

  • Brown, J. J., Davies, D. L., Ferriss, J. B., Fraser, R., Haywood, E., Lever, A. F., Robertson, J. I. S.: Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. Brit. med. J. 1972 II, 729–734

  • Castro, J. E., Griffiths, H. J., Edwards, E. D.: A double-blind, controlled, clinical trial of spironolactone for benign prostatic hypertrophy. Brit. J. Surg. 58, 485–491 (1971)

    Google Scholar 

  • Friedberg, C. K.: Clinical pharmacology and therapeutic use of spirolactones, antialdosterone agents. In: Edema, mechanism and management, p. 316. J. H. Moyer and M. Fuchs, eds. Philadelphia-London: W. B. Saunders 1960

    Google Scholar 

  • Kagawa, C. M.: The pharmacology of antialdosterone agents (spirolactones). In: Edema, mechanism and management, p. 309. J. H. Moyer and M. Fuchs, eds. Philadelphia-London: W. B. Saunders 1960

    Google Scholar 

  • Kuschinsky, G., Lüllmann, H.: Kurzes Lehrbuch der Pharmakologie, 6. Aufl., pp. 82–83. Stuttgart: Thieme 1974

    Google Scholar 

  • Spark, R. F., Melby, J. C.: Aldosteronism in hypertension. Ann. intern. Med. 69, 685–691 (1968)

    Google Scholar 

  • Steelman, S. L., Brooks, J. R., Morgan, E. R., Patanelli, D. J.: Antiandrogenic activity of spironolactone. Steroids 14, 449–450 (1969)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Pharmakologie der Medizinischen Hochschule Hannover, Karl-Wiechert-Allee 9, D-3000, Hannover-Kleefeld, Federal Republic of Germany

    H. C. Erbler

Authors
  1. H. C. Erbler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Erbler, H.C. Suppression by the spironolactone metabolite canrenone of plasma testosterone in man. Naunyn-Schmiedeberg's Arch. Pharmacol. 285, 403–406 (1974). https://doi.org/10.1007/BF00501468

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00501468

Key words

Search

Navigation